China’s Hisun Gets Capreomycin WHO Prequalification
This article was originally published in PharmAsia News
Executive Summary
Hisun’s pre-qualification approval for capreomycin to treat second-line active tuberculosis cases may help bring costs down for a drug increasingly in demand as multi-drug resistant patients multiply worldwide.